Full-Time

Senior Reimbursement Analyst

Pvh

Posted on 11/21/2025

Deadline 11/23/25
Medtronic

Medtronic

10,001+ employees

Medical device maker advancing therapies

Compensation Overview

$98.4k - $147.6k/yr

+ MIP + Short-term incentive

Minneapolis, MN, USA

Hybrid

Preferred Plymouth, MN location; remote assignment possible for exceptional candidates; travel ~10-15%.

Category
Finance & Banking (1)
Requirements
  • Bachelor’s degree and minimum of 4 years experience in health policy, reimbursement, health economics, health services research
  • Or an advanced degree with a minimum of 2 years experience in health policy, reimbursement, health economics, health services research
Responsibilities
  • Develops and implements reimbursement strategies and programs for existing and new therapy expansions and indications to obtain coding, coverage, payment, and funding, in collaboration with global colleagues.
  • Collaborates with cross functional partners (marketing, regulatory, legal, R&D, clinical, medical science, corporate and global reimbursement counterparts) and business leaders on U.S. reimbursement strategies and programs, health economics, evidence strategy, and health policy.
  • This may include direct interactions with payers and other related entities to gain reimbursement for Medtronic therapies.
  • Leads U.S. launch customer engagement on HEPR topics.
  • Creates and delivers training and education programs to sales force, physicians, medical directors, billing personnel, distributors, and other external stakeholders, and ensures other trainers are supported and educated appropriately.
  • Develop and deliver educational programs and presentations related to reimbursement topics.
  • Contribute to reimbursement education programs to internal and external audiences.
  • Drives and owns the development and maintenance of reimbursement tools to be used by reimbursement colleagues and sales partners (coding sheets, economic models, evidence dossiers, etc.).
  • Represents the HEPR functional perspective and provides input to product development teams, clinical study teams, marketing, sales, regulatory, clinical, medical science, and other business leaders.
  • Partners closely with in-country and business unit teams understand and develop localized health economic and reimbursement value stories for Medtronic therapies to drive reimbursement strategies.
  • Works closely with Health Economics and Outcomes Research team to evaluate the economic impact of the use of therapies/products on payers, including the government.
  • Creates and executes comprehensive market access strategies through the integration of U.S. reimbursement mechanisms and policies, pricing, health technology assessment, evidence-based medicine review, and health economic modeling activities.
  • Serves as subject matter expert for internal and external customers regarding coding, coverage and payment associated with PVH products and therapies.
  • Serve as point of contact for incoming questions and inquiries regarding coding, coverage and payment from field sales, field reimbursement, and external physician and hospital providers.
  • Leverage coding and billing expertise to engage in chart reviews, in accordance with compliance policies.
  • Leads the development and maintenance of coding, coverage, and payment information and tools that support customer understanding and education.
  • Develop proactive solutions (tools, FAQs, etc.) that facilitate customer understanding and education.
  • Partner with other team members and the US Regional Economic Managers on critical coding, coverage and payment hospital focused messages and development of tools and customer resources.
  • Provides therapy and product-specific support and analysis to the field in the areas of US reimbursement rules and regulations for commercially released products in PVH.
  • Maintain a comprehensive knowledge of the rules and regulations of CMS as well as major commercial payers.
  • Reviews and understands U.S. reimbursement and payment systems, including Medicare payment systems, payer coverage policies, claims data sets, and sources of U.S. health data.
  • Partners with industry stakeholders and physician societies in the development and implementation of reimbursement strategies and to complete market access submissions.
  • Identifies payer opportunities and issues and implements programs to resolve/decrease barriers to entry for the company's products or therapies.
  • Stays actively informed on US, global, and regional reimbursement trends and payment policy changes to proactively identify opportunities & risks to market entry, and to inform and evolve reimbursement strategy.
  • Creates and manages interactive dashboards, reports, and similar content.
  • Functions confidently in a matrixed, complex organization to assess, recommend, and implement solutions, and is comfortable in fast-moving business environments.
  • Works comfortably and adeptly with colleagues across multiple geographic settings, virtual and office-based, and with a variety of business functions.
Desired Qualifications
  • Advanced degree (MPH, MS, MHA, MBA, PhD) or post-graduate training in health policy, health services research, economics, biostatistics, epidemiology, public administration, health sector management, or a related discipline
  • One or more of the following coding credentials: RHIA, CCS, CCS-P, CPC, CCC, or CIRCC
  • 5+ years device or pharmaceutical industry experience, or experience in payer/provider/ health system healthcare economics and reimbursement
  • Knowledgeable in U.S. hospital-based medical device reimbursement, including U.S. healthcare coding (HCPCS/CPT, ICD-10), Medicare payment systems, and Medicare and U.S. commercial payer coverage processes
  • Familiar with health economic methods, including payer-focused evidence development, cost-effectiveness analyses and budget impact models
  • Project management experience leading large projects or processes, initiatives, and cross-functional teams with results orientation, quality orientation, proactive, with attention to detail, in a variety of situations of varying ambiguity
  • Ability to work effectively and collaboratively across cultures in a global organization
  • Ability to independently coordinate and prioritize multiple projects simultaneously
  • Experience leading change management or process improvement initiatives
  • Demonstrated ability to strategically apply technical knowledge to a variety of business situations and to translate across various functional groups
  • Demonstrated influence management skills and ability to work effectively in a complex, matrixed organization
  • Demonstrated experience with evidence development, assessment, or synthesis
  • Able to work independently and as part of a team to proactively solve problems and drive work forward, performing with limited oversight and supervision
  • Excellent verbal and written communication and presentation skills to all levels of the organization
  • Able to apply strong analytical skills to learn quickly, identify opportunities, and solve problems of varying ambiguity
  • Strong results orientation, quality orientation, proactive, with attention to detail, in a variety of situations of varying ambiguity
  • Demonstrated experience collaborating effectively with colleagues across multiple geographic settings, virtual and office-based, and with a variety of business functions.
  • Highly motivated and capable of comprehending large amounts of technical content, which is then communicated in a clear, concise fashion
  • Advanced presentation and computer skills
  • Skilled with analytical tools (e.g., PowerBI, Tableau), CRMs (e.g., Salesforce)

Medtronic makes medical devices and therapies to treat chronic diseases, including implantables, sensors, and diabetes management tools. Its devices interact with the body to regulate or monitor functions, such as pacemakers delivering heart stimulation and neuromodulation devices sending electrical signals. The company differentiates itself through a long history of device development and a broad portfolio, expanded via acquisitions to access new technologies and markets. Its goal is to improve patient health outcomes by providing integrated medical technologies that help manage chronic conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Fridley, Minnesota

Founded

1949

Simplify Jobs

Simplify's Take

What believers are saying

  • Sphere-9 catheter achieves 65.5% VT-free rate at six months, earning FDA Breakthrough Designation.
  • Stealth AXiS gains CE mark for AI-powered navigation in spine and cranial procedures.
  • 20M investment in Orchestra BioMed advances BACKBEAT hypertension trial commercialization.

What critics are saying

  • ShinyHunters breach exposes 9M records, sparking lawsuits and eroding provider trust by Q3 2026.
  • Santa Rosa closure cuts 370 jobs, disrupting cardiovascular innovation by spring 2028.
  • MiniMed IPO spins out diabetes unit, slashing $5B revenue to Abbott's FreeStyle Libre.

What makes Medtronic unique

  • Medtronic's Percept DBS system uses BrainSense technology for closed-loop adaptive stimulation.
  • Percept automatically adjusts to Parkinson's symptom fluctuations like tremor and rigidity.
  • FDA approved Medtronic's closed-loop DBS as milestone ahead of Abbott and Boston Scientific.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Employee Assistance Program

Wellness Program

Company News

Yahoo Finance
Apr 10th, 2026
GE HealthCare and Medtronic launch integrated neurosurgery imaging and navigation system

Medtronic and GE HealthCare have launched a digital integration combining GE's bkActiv intraoperative ultrasound with Medtronic's Stealth AXiS surgical navigation system for cranial neurosurgery. The commercially available system provides real-time imaging during procedures, connecting Medtronic's navigation and robotics platforms with GE HealthCare's imaging technology. The integration aims to enhance clinical decision-making during complex cranial procedures through precise guidance and visualisation. It may influence hospital equipment purchasing decisions, surgeon productivity and operating room efficiency. Medtronic currently trades at $87.91, approximately 19.8% below the $109.64 analyst target range midpoint. The stock has experienced a 2.2% decline over the past 30 days. Adoption rates amongst surgeons and hospitals, alongside hospital capital spending on neurosurgery suites, will be key factors to monitor.

The Associated Press
Apr 9th, 2026
GE HealthCare integrates bkActiv ultrasound with Medtronic Stealth AXiS for real-time cranial surgery navigation

GE HealthCare has announced a digital integration between its bkActiv intraoperative ultrasound system and Medtronic's Stealth AXiS surgical navigation system, now commercially available for cranial procedures. The integration allows neurosurgeons to use bkActiv as a plug-and-play real-time visualisation solution during procedures. The system addresses "brain shift", a natural movement of the brain during surgery that reduces pre-surgical image accuracy. bkActiv provides live ultrasound images alongside pre-operative MRI or CT scans on the Stealth AXiS system, recently cleared by the FDA for cranial procedures in the United States. Features include sterilisable transducers, sensitive colour Doppler for blood flow visualisation, and remote control capability from the sterile field. The companies will showcase the integration at the American Association of Neurological Surgeons Annual Scientific Meeting in May 2026.

Yahoo Finance
Apr 7th, 2026
Stifel cuts Medtronic price target to $95 from $105 on MiniMed IPO dilution

Stifel has lowered its price target on Medtronic (NYSE:MDT) to $95 from $105, maintaining a Hold rating. The adjustment reflects transaction-related impacts from the 9 March IPO of Medtronic's Diabetes business, now called MiniMed. MiniMed will remain a consolidated subsidiary until formal separation, expected about six months post-IPO. Stifel continues to model full Diabetes business revenue whilst adjusting for the 10% non-controlling interest sold in the IPO. Management expects IPO-related earnings per share dilution of 1-2 cents monthly until separation completes. Separately, the US Food and Drug Administration recently cleared Medtronic's Stealth AXiS surgical system for cranial and ear, nose and throat procedures, expanding beyond its earlier spine indication.

Silicon Republic
Apr 3rd, 2026
What impact might Medtronic's new lab have on Galway's medtech ecosystem?

What impact might Medtronic's new lab have on Galway's medtech ecosystem? 3 Apr 2026 From left: Ruth Callanan, Ronan Rogers and John Caulfield. Image: Andrew Downes/Xposure Ronan Rogers and Ruth Callanan discuss innovation in the west of Ireland and the evolution of Ireland's STEM careers. Ireland's medtech sector is moving beyond traditional biomedical engineering, according to Ronan Rogers, the senior R&D director for cardiac ablation solutions at Medtronic. He explained the region has built "real depth", not just in medtech, but across key areas such as pharmaceutical science, advanced analytics and digital technology. Areas that are now "increasingly converging". "That diversity of opportunity is a huge strength for Ireland," he told SiliconRepublic.com. "It allows people from different professional backgrounds to find meaningful, high-impact careers in healthcare, while helping Ireland move further up the value chain as a centre for complex, globally relevant innovation." Having recently expanded its Galway-based pharmaceutical laboratory, the Medtronic facility now serves as a west of Ireland hub for high-tech innovation and the evolving needs of the global healthcare space. Rogers is of the opinion that this is reflective of the convergence of the country's medtech divisions. Noting that the primary purpose of the lab "is to integrate pharmaceutical, engineering and analytical expertise under one roof to address the complex challenges of combination products, [that is] where a medical device and a medicine work together". "We see that convergence very clearly in this laboratory and there is a wide range of career paths in our industry, whether that's a pharmacist drawn to the faster innovation cycles and applied science of medtech, or a software developer who wants to use their skills to solve real healthcare challenges and code with a deeper sense of purpose." What opportunities exist? With the expansion comes the opportunity for students and professionals to consider a new role, either as part of Medtronic or within Galway's thriving life science and medtech spaces. "Galway offers a unique innovation ecosystem where infrastructure, academic partnerships and a significant medtech footprint all provide a strong foundation for sustaining Ireland's leadership in the life sciences sector," said Ruth Callanan, Medtronic's director of site quality. With the investment focused on significantly expanding R&D capability and technical depth within a critical space in the Irish medtech sector, Medtronic has increased lab space by almost a half and introduced analytical technologies that didn't exist there before. Callanan said: "This creates the conditions for future high-value work as programmes grow. It strengthens Galway's ability to attract and retain highly specialised talent, pharmaceutical scientists, chemical and materials engineers and it allows work that was previously outsourced internationally to be done here in Ireland. "Over time, as demand and activity scale, we do expect this capability to support additional specialist roles, phased in over the coming years. Importantly, it reinforces Ireland's position at the forefront of advanced medtech R&D and reflects a broader industry trend toward self-sufficiency in high-tech analytical testing." Step into the future. She explained the new lab will enable experts to integrate processes as the facility will be responsible for the entire life cycle of product development, from early phase R&D through to post-market oversight. She added: "The laboratory utilises advanced LCMS [liquid chromatography-mass spectrometry] and GCMS [gas chromatography-mass spectrometry] technologies, which act as 'molecular microscopes'. This allows our scientists to identify unknown compounds or impurities at extremely precise levels." According to Rogers, the new lab has a role to play in what he believes to be the reshaping of how STEM careers in Ireland are perceived and pursued, with Callanan noting this creates for students and professionals opportunities to engage with careers that bridge the gap between various scientific disciplines. "A laboratory of this size and complexity requires students and professionals with a wide range of skills and experience across multiple disciplines," she said. "Just as importantly," added Rogers, "we're sending a clear signal to pharmacists, chemists and analytical scientists that medtech offers deep, intellectually challenging career paths that go well beyond traditional manufacturing or even classical biomedical engineering." Laura Varley is the Careers editor for Silicon Republic

The Irish Post
Mar 31st, 2026
Medtronic launches new pharmaceutical lab in Galway.

Medtronic launches new pharmaceutical lab in Galway. A GLOBAL health tech leader which is headquartered in Galway has unveiled a new laboratory in the city. Medtronic has formally opened a new Pharma Laboratory and Building 6 at its location in Parkmore. Galway TD and Minister of State Seán Canney attended the launch event this month. Minister Seán Canney (centre) attended the opening of the new laboratory this month "Great to be in Parkmore to officially open the new Pharma Laboratory and Building 6 at Medtronic," he said. "This is a really significant investment for Galway and for the West - strengthening our position as a global leader in MedTech and supporting the next generation of innovation." He added: "The facility will act as a "one-stop shop" for testing and validating drug-device combination products - a fast-growing area that is improving outcomes for patients worldwide. "Medtronic has been part of Galway for over 40 years, and what's been built here is genuinely world-class. "It reflects the strength of the talent, the ecosystem, and the ambition that exists across this region. Most importantly, this is about impact - better treatments, better technologies, and better outcomes for patients. "A real vote of confidence in Galway and in Ireland." Everything from irishpost.com and the print edition is available on the Irish Post App - plus more! Download it for Android or Apple IOS devices today.

INACTIVE